Cargando…
Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro
Cardiovascular disease has become the primary disease that threatens human health and is considered the leading cause of death. Cardiac remodeling, which is associated with cardiovascular disease, mainly manifests as cardiac hypertrophy, fibrosis, inflammation, and oxidative stress. Farrerol plays a...
Autores principales: | He, Jian, Xu, Dengyue, Wang, Lu, Yu, Xiaohong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846078/ https://www.ncbi.nlm.nih.gov/pubmed/36686707 http://dx.doi.org/10.3389/fphar.2022.1079251 |
Ejemplares similares
-
A Complete Study of Farrerol Metabolites Produced In Vivo and In Vitro
por: Yin, Jintuo, et al.
Publicado: (2019) -
Farrerol Alleviates Myocardial Ischemia/Reperfusion Injury by Targeting Macrophages and NLRP3
por: Zhou, Lin, et al.
Publicado: (2022) -
Neohesperidin Protects Angiotensin II-Induced Hypertension and Vascular Remodeling
por: Zhang, Jingsi, et al.
Publicado: (2022) -
Blocking VCAM-1 Prevents Angiotensin II-Induced Hypertension and Vascular Remodeling in Mice
por: Yin, Liangqingqing, et al.
Publicado: (2022) -
Farrerol Ameliorated Cisplatin-Induced Chronic Kidney Disease Through Mitophagy Induction via Nrf2/PINK1 Pathway
por: Ma, Ning, et al.
Publicado: (2021)